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Summary
Stanniocalcin (STC) decreases branchial Ca2+-uptake in fish. In order to determine its bioactive domain, 
synthetic fragments (U amino acids (aa) 1-20; V aa 103-136; W aa 202-231) of eel STC were tested for their effect 
on Ca2  ^ uptake in tilapia (Oreochromis mossambicus). Ca2" uptake was inhibited by an N-terminal fragment but 
not by a midfragment nor a C-terminal fragment of the mature hormone. We provide theoretical and experimental 
evidence that a midportion of STC, which is included in the synthetic fragment V, is the most antigenic site of the 
molecule. Polyclonal antibodies against stanniocalcin are directed against this midportion although this region of 
STC appears not to be essential for signal transduction. These results suggest that the currently available antibodies 
will recognize inactive STC fragments in the circulation. We conclude that the bioactive portion of STC does not 
correspond with the major antigenic portion of the hormone. The results imply that studies on plasma STC levels 
employing a polyclonal antiserum against STC should be interpreted with care.
Introduction
The corpuscles of Stannius (CS) are unique en­
docrine glands in bony fishes, associated with the kid­
neys. They produce the glycosylated hypocalcemic hor­
mone stanniocalcin (Flik, 1990). It is generally ac­
cepted that stanniocalcin (STC) is an inhibitor of cal­
cium uptake in fish (Wagner et al., 1986; Lafeber et al., 
1988a). Lafeber et al. (1988b) provided the first direct 
evidence that the gills are a primary target for STC. 
They measured Ca2+ fluxes in intact trout and in a 
trout isolated head preparation and concluded that the 
degree of Ca2+ influx inhibition by STC was compara­
ble in both preparations. The branchial Ca2 f efflux 
was not affected by the hormone (Lafeber et al., 1988a, 
b). Thus STC specifically inhibits branchial Ca2 + in­
flux.
Correspondence to: Dr. P.M. Verbost, Dept, of Animal Physiol­
ogy, Faculty of Science, University of Nijmegen, Toernooiveld, 6525 
ED Nijmegen, Netherlands.
Using recombinant DNA techniques, Butkus et al. 
(1987) revealed the nucleotide sequence of STC (eSTC) 
in the Australian eel ( Anguilla australis). Proceeding 
from the deduced amino acid (aa) sequence of this 
eSTC, hormone fragments were synthesized; an N- 
terminal, a C-terminal and a midfragment. In juvenile 
trout (Oncorhynchus my kiss) the N-terminal fragment 
of eSTC showed Ca2+ influx inhibiting activity (Butkus 
et al., 1989; Milliken et al., 1990). In the present study 
we provide more data in favor of the hypothesis that 
the N-terminus is the bioactive portion of the molecule 
which may be related to the high degree of amino acid 
sequence conservation in teleostean species (Butkus et 
al., 1989). The reasoning was that the N-terminus 
should inhibit Ca2" influx in other fish species as well. 
We determined the effects of the N-terminus on Ca2 + 
influx in tilapia (Oreochromis mossambicus) and, for 
comparison, tested the effects of a midfragment and a 
C-terminal fragment. Milliken et al. (1990) found stim­
ulatory effects of the C-terminal peptide in juvenile 
trout, but only when the Ca2+ influx in these fish was 
very low. The midfragment has never been tested in 
the Ca2+ uptake assay before.
The bioactive domain of STC does not necessarily 
correspond with the antigenic domain. However, when 
circulating hormone levels are to be measured in a 
radioimmunoassay (R IA ) or in an enzyme-linked im­
munosorbent assay (ELISA) the precise location of the 
epitope should be known. It is possible for an antibody 
to be directed against an inactive portion of the hor­
mone that is split off and stays in the blood circulation 
much longer than a bioactive fragment. This is because 
an antibody, raised against a protein, generally recog­
nizes just a small portion of the molecule. The early 
measurements of parathyroid hormone (PTH) levels in 
terrestrial vertebrates illustrate the problem. Antibod­
ies initially used in PTH RIAs were directed against 
the mid or carboxyl-terminal portion of the hormone 
(Nussbaum et al., 1985). These RIAs detect biologically 
inactive fragments of the hormone present in approxi­
mately 1 0-fold higher concentration than intact hor­
mone. Such assays, at best, are only an index of PTH 
secretion (Nussbaum et al., 1985).
In various studies the specificity of antisera raised 
against STC has been shown (Butkus et al., 1987; 
Kaneko et al., 1988; Wagner et al., 1988). It is not 
known, however, against which portion of the molecule 
it is directed. In the present study we first analyzed 
eSTC for possible antigenic sites in the molecule. Sec­
ondly, by means of ELISAs and dot blotting im­
munoassays on eSTC peptides the fragment that is 
recognized by currently available antisera was deter­
mined. Thirdly, we compared the immunoreactivity 
and the N-terminal amino acid sequence of fully bioac­
tive STC and that of an STC preparation with impaired 
bioactivity.
Materials and methods
Fish
Freshwater tilapia (Oreochromis mossambicus) rang­
ing in weight from 20 to 40 g were obtained from a 
laboratory stock. Fish were kept at 27°C in city of 
Nijmegen tapwater that contains (in mmol* I-1): 0.8 
Ca2+, 0.20 Mg2+, 0.61 N a+, 0.05 K +, 0.66 C l", 0.32 
S O j"  and 3.15 H C O r .
Analytical methods
The calcium content of the water was determined 
colorimetrically with a diagnostic kit (Sigma). Tracer 
content of water samples and tissue digests was deter­
mined by liquid scintillation analysis. Aqueous samples 
(0.5 ml) were mixed with 4.5 ml of Aqualuma scintilla­
tion fluid. Protein was measured with the Lowry (1951) 
method using bovine serum albumin (BSA) as a refer­
ence.
V
O)
o
o
o 2 
£
o
i
LL
1
I
control
tS T C
U
V
w
tSTC
Fig. I. Whole body Ca: + influx after injection of eSTC synthetic 
fragments U, V or W (5 nmol g ’ ), native tSTC ( I -231) or tSTC' 
(half 5-231, half 1-23 0  (0.5 nmol g *). Bars represent means of six 
fish + SEM. Significance (* P <0.05) tested with the Mann-Whitney
U-test.
as described in detail before (Lafeber et al., 1988a). In 
the second step a size separation was performed with 
the SMART system (Pharmacia/LKB) on a Superdex 
75 HR 10/30 column (high performance gel filtration 
column). Preparations thus obtained are essentially 
free of contaminants as established by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE) and Western blotting. Bioactivity is assessed by 
determining the Ca2" influx reducing potency in trout 
(results not shown) and tilapia (this study).
To produce STC with impaired activity a batch of 
freshly isolated corpuscles of Stannius was left at room 
temperature for 24 h before isolation of STC was 
started. This STC batch (STC') possessed 50% of the 
bioactivity of native STC (Fig. 1 ).
Fragments of the Australian eel STC (eSTC) were 
synthesized at the Howard Florey Institute Peptide 
Laboratory (Butkus et al., 1989). The following three 
peptides were used: peptide U: N-terminal (1-20) se­
quence of eSTC; peptide V: mid (103-136) sequence of 
eSTC; peptide W: C-terminal (202-231) sequence of 
eSTC. Freeze-dried peptides were air-shipped from 
Parkville, Australia directly following synthesis.
Bioassay (Ca2+ uptake)
The bioassays were conducted as described by Ver­
bost et al. (1989). Fish were placed in opaque Perspex 
boxes (volume: 1.5 liter water) and ^CaC l (1.0 MBq • 
l “ 1) was added after the water flow’ had been stopped. 
Uptake of Ca2  ^ was calculated from the radioactivity 
accumulated in the fish after 3 h exposure to 4>Ca and 
the mean 4>Ca specific activity of the water. Ca2 + 
uptake (FiU) data were normalized to fish weight (Flik 
et al., 1985) and expressed in ¿¿mol • h~ 1 per 100 g fish 
weight.
Hormone preparation Hormone injections
Trout STC (tSTC) was purified in two steps. The The peptides were dissolved in demineralized water
first step was concanavalin-A affinity chromatography as 5 mmol-I - 1  stock solutions that were diluted in
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saline immediately before injection. STC (0.5 nmol per 
g fish) and synthetic hormone fragments (5 nmol per g 
fish) were all freshly dissolved and injected intraperi- 
toneally (10 /xl/g) 1 h before tracer exposure. Injection 
of saline served as control.
Antigenic sites o f STC
Using the primary structure of Australian eel STC, 
the molecule was analyzed for possible antigenic sites. 
A combination of hydrophilicity, accessibility and mo­
bility parameters has been used in algorithms to pre­
dict which sequences of amino acid residues of STC 
compose antigenic sites. This method (Parker et al., 
1986) predicts surface sites (expressed as surface value) 
that correlate very well with antigenic sites. It should 
be noted that in this kind of analysis the carbohydrate 
moiety of STC (Butkus et al., 1987) is not included.
Dot blotting immunoassay
2 fig STC or CS extract and 1 ¡ig synthetic hormone 
fragment were blotted directly on nitrocellulose mem­
brane using a glass capillary. Immunostaining was per­
formed as described in detail by Flik et al. (1990) for 
Western blots with RADH-III, a polyclonal antiserum 
raised against tSTC (Kaneko et al., 1988), as the pri­
mary antibody in a 1:5000 dilution. With two other 
antisera, ECS-I and ECS-III, raised against native 
eSTC (Butkus et al., 1987), the same type of dotting 
immunoassay was performed.
Enzyme-linked immunosorbent assay
A competitive ELISA for STC, developed by 
Mayer-Gostan et al. (1992), was used to quantitate 
STC levels in plasma samples. This technique is based 
on competition between free STC in standard or plasma 
samples and STC immobilized on microtiter plates for 
the STC antibodies. The trout STC antiserum used
(RADH-III; Kaneko et al., 1988), has a high degree of 
crossreactivity with eel STC. Purified trout STC 
(Lafeber et al., 1988a) served as a standard.
The wells of microtiter plates were coated with 
tSTC (1.85 nmol -1 1) in 200 i± 1 of coating buffer (0.05 
mol • 1 1 sodium bicarbonate buffer, pH 9.6), except 
for the wells in the first column of the plate which 
received 200 /±\ of a BSA solution of equivalent protein 
content in coating buffer (blanks). Coating lasted for 1 
h at 37°C; coated plates were stored at 4°C. Between 
incubation steps, coated plates were rinsed with wash­
ing buffer (0 .0 1  M sodium phosphate buffered saline 
(PBS), pH 7.4, with 0.05% Tween-20; Bio-Rad). For 
competition, antigen and RADH-III antiserum were 
diluted in dilution buffer (i.e. washing buffer contain­
ing 2% porcine serum). Equal volumes of antigen and 
diluted antiserum (1 : 2 0 , 0 0 0  to 1 :320,000) were incu­
bated in 4 ml Minisorp tubes (Nunc) for 16 h at 20°C. 
Under these conditions the binding of RADH-III to 
the STC-coated wells was competitively reduced by 
STC in a sigmoidal fashion; 50% reduction of signal 
was obtained with 1.7-2.2 nmol • I 1 STC. Tubes con­
taining diluted antiserum only were incubated under 
the same conditions. After washing, the wells of coated 
plates were blocked with 2 0 0  /jl 1 of dilution buffer 
(containing 2% pork serum) for 1 h at 37°C. The plates 
were washed and filled with 2 0 0  fi\ per well of the 
antigen/antiserum mixture except for the wells in 
columns 1 (blanks) and 2 (B {]) which received 2 0 0  ¡i\ of 
the diluted antiserum. Plates were incubated for 2 h at 
3 7 °C The wells were washed and incubated with 2 0 0  
¡i\ of goat anti-rabbit peroxidase immunoconjugate 
(Nordic) in dilution buffer (1:5000) for 1 h at 37°C. 
For quantification of the immunoconjugate bound to 
the wells, an enzymatic reaction was used with o-phen- 
ylenediamine (OPD; Sigma) as a substrate. After wash­
ing, 200 ¡i 1 of substrate (0.05% OPD in citrate/
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Fig. 2. Surface profile for eSTC obtained by combining hydrophilicity, accessibility and flexibility parameters
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Fig. 3. Immuno-dot blot of CS extract, STC and fragments U. V and W. The blots were probed with three independently raised CS antibodies, 
RADH-I1I, ECS-I and ECS-III. A l: goat serum (4 ¿¿g); A3: trout CS-extract; Bl: fragment U; B2: fragment V: B3: fragment W; C l: tSTC; C3:
cSTC.
phosphate buffer; 0.2 mol l - 1  Na: H P 0 4, 0.1 mol • 1 1 
citric acid, pH 5.0, with 0.025% hydrogen peroxide) 
was added. The reaction was allowed to proceed for 
20-30 min in the dark and was stopped by adding 50 
/j l\ of 2 mol - I " 1 H : S 0 4. Absorbance was measured at 
492 nm in a microplate reader (Titertek).
Results
Effects o f hormone fragments on Ca 2 4 influx
Fig. 1 shows the effects of injection of tSTC or 
hormone fragments on Ca2  ^ influx. tSTC and peptide 
U (aa 1-20) decreased the influx, whereas V (aa 103— 
136) and W (aa 202-231) had no effect. ‘STC' isolated 
from corpuscles left for 24 h at room temperature 
(tSTC') showed only 50% of the Ca2' influx reducing 
effect compared to intact tSTC; this tSTC' induced 
inhibition of Ca2+ influx was not significant. Amino 
acid sequence analysis (by Edman degradation method 
performed at the Protein Sequencing Facility, Depart­
ment of Medical Biochemistry, State University of Lei­
den, Netherlands) shows that 50% of tSTC' lacks the 
first 4 N-terminal amino acids (Phe-Ser-Ser-Asn). The 
other 50% carries the complete N-terminus as deter­
mined for active tSTC (Phe-Ser-Ser-Asn-Ser-Pro-Ser- 
Asp-Val-Ala-etc.; Lafeber et al., 1988a). The propor­
tion of bioactivity that is lost correlates well with the 
amount STC molecules that is truncated.
Antigenic sites o f eSTC
A surface area plot based on the amino acid back­
bone of eSTC (see Materials and methods) is shown in 
Fig. 2. The sequences covered by the synthetic frag­
ments U, V and W are indicated with horizontal bars. 
In native STC the carbohydrate group is linked N-gly-
cosidically at position 29. Residues with composite 
profile values greater than 50% represent potential 
antigenic sites. Fig. 2 shows large potential antigenic 
sites in the regions covered by fragments V and W. 
Besides these two there are six smaller peaks that 
surpass the 50% one of which is localized in fragment
U.
Crossreactivity o f anti-STC with hormone fragments 
The immuno-dot blots (Fig. 3) show that fragment 
V, but not U or W, is recognized by the antisera 
RADH-II1, ECS-I and ECS-III, but no recognition of 
U or W. RADH-III crossreacts with both CS extracts 
and purified STC of trout and carp.
antigen (nM)
Fig. 4. Antigen dilution curves for tSTC and fragment V obtained 
with a competitive ELISA applying anti-STC (RADH-III, 1:20, 000). 
The wells of the microtiter plates were coated with tSTC. The results 
of two separate experiments in duplicate are presented.
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In an ELISA using the trout STC antibody RADH- 
III, the results obtained with the dot blots were con­
firmed and extended. We used antibody dilutions from 
1 : 2 0 , 0 0 0  to 1 :320,000 and found no binding of peptide 
U or W. With peptide V a similar type of binding as 
with STC seems to occur (Fig. 4) since the linear parts 
of the dilution curves run parallel (the gradient for
STC is —1.36 + 0.10; the gradient for V is —1.18 +
0.20). The affinity for V is approximately 100 times 
lower than for tSTC. To verify the specificity of the 
staining reactions obtained with fragment V we also 
tried another rabbit serum (anti-prolactin; in this case 
the wells were coated with prolactin) but this showed 
no crossreactivity (results not shown). The binding 
characteristics of tSTC' (the non-bioactive prepara­
tion) tested in the STC ELISA were the same as for 
bioactive tSTC (as in Fig. 4; results further not shown).
Discussion
Bioactivity
The N-terminal eSTC fragment, U, inhibits Ca2" 
influx in tilapia whereas the mid-portion, V, and the 
C-terminal, W, of the molecule have no effect. We 
conclude that the N-terminal fragment carries a, and 
possibly the, bioactive amino acid sequence of STC. It 
should be noted, nonetheless, that 10 times higher 
concentrations of the N-terminal fragment (5 nmol/g 
fish) are needed to obtain a similar Ca: * influx inhibi­
tion as with tSTC (0.5 nmol/g). However, at least four 
conceivable explanations may be given for this differ­
ence. Firstly, it could be a species specific difference; 
eSTC and its fragments could be less effective in 
tilapia than tSTC. Secondly, it also could be that the 
fragment is too small to produce the same bioactivity 
as the native hormone. An analogous situation was 
reported for parathyroid hormone (PTH, 84 residues) 
in mammals, where 1-34 PTH gives maximal bone 
resorbing and hypercalcemic responses whereas 1-28 
or 3-34 PTH fragments have a much lower potency 
(Habener and Potts, 1976; Herrmann-Erlee et al., 
1983). Thirdly, the native hormone is a dimer (Lafeber 
et al., 1988a), in contrast to U. Possibly, this dimeric 
constitution renders STC its maximal bioactivity. 
Fourthly, the carbohydrate group which is attached at 
position 29 in the native hormone (Butkus et al., 1987) 
may be required for optimal receptor activation and 
obviously this moiety is absent in U. It is generally 
believed that the carbohydrates of glycoprotein hor­
mones are essential for their complete biological activ­
ity in target cells although the oligosaccharide moiety 
may not be necessary for receptor binding (Sairam,
1989). In any case it is clear that fragment U reduces 
Ca2 * influx in addition to the effect of the endogenous 
STC in the fish.
The midportion of the hormone (V) did not affect
Ca2" influx. Although V alone appears unable to acti­
vate the STC receptor as no decrease in Ca2 + influx 
occurred, it may still be that receptor binding of the 
midportion is needed to reach full activity or the mid­
portion may play a role in defining the three-dimen­
sional structure of the molecule so that full receptor 
binding of STC can occur. Also the C-terminal frag­
ment (W) has no effect on Ca2 * influx in tilapia. In 
analogy to V, W appears not to affect the STC recep­
tor. Milliken et al. (1990) showed stimulatory effects of 
the C-terminus (W) on Ca2" influx in juvenile trout 
and explained the effect as an antagonistic action on 
the binding of endogenous hormone. The enhance- 
ment in Ca~f uptake by W was only found when the 
fish were at the nadir of an apparent Ca2" uptake 
cycle (calcium uptake varied from 0.33 to 4.88 ¿¿mol • 
h 1 • 100 g 1). We do not find a cycling in Ca2 f uptake 
in tilapia nor trout. Compared to juvenile trout, tilapia 
have a constantly high uptake rate. This may explain 
why we did not see stimulatory effects of the C-termi­
nal fragment on Ca2+ uptake in tilapia.
Hormone isolated from corpuscles of Stannius that 
had been left at room temperature for 24 h (tSTC') 
was deficient in reducing Ca2" influx. The molecular 
size of this tSTC' was checked with polyacrylamide gel 
electrophoresis and gel permeation chromatography 
but was not significantly different from bioactive tSTC 
(results not shown). In an amino acid analysis tSTC' 
gave two signals, showing that roughly 50% of the 
tSTC' had lost the four N-terminal amino acids. The 
other 50% carried the complete N-terminus identical 
to that of intact tSTC that gives one signal in the 
amino acid analysis (identical to Lafeber et al., 1988a; 
results further not shown). This suggests an important 
role for the N-terminus in determining the bioactivity.
Antigenicity
Our results indicate that polyclonal STC-antisera, 
whether raised against trout or eel STC, recognize a 
midfragment of eSTC but not the N-terminus that is 
required for bioactivity, or the C-terminus.
According to its amino acid sequence STC has 11 
surface areas that are likely to be antigenic. The termi­
nal regions, especially the C-terminal, show large anti­
genic sites. Still, no antibodies directed against these 
sites have been produced. The midfragment conceiv­
ably contains a major antigenic site of the hormone 
(Fig. 2). That the site is very antigenic is confirmed by 
the observation that three independently produced 
polyclonal antisera raised against STC specifically rec­
ognize fragment V (Fig. 3). The main difference be­
tween the midregion and the terminal regions lies in 
the flexibility; compared to the midregion, the N- 
terminus is rigid and the C-terminus is even more rigid 
because of frequently occurring prolines in the C- 
terminus (review by Suzuki, 1988). The flexibility ap­
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pears to be very important for the antigenicity of STC 
portions. This is in agreement with notions from crys­
tallography and nuclear magnetic resonance (NMR) 
studies (Tainer et al., 1984; Westhof et al., 1984) that 
the more flexible regions of a protein become epitopes. 
A high flexibility of the midregion may explain why the 
different antibodies were directed against this portion
of STC.
One could argue that in the determination of sur­
face areas the glyco group of the hormone (positioned 
at amino acid 29) is disregarded as a potential epitope. 
Sugar residues are generally highly antigenic. However, 
this appears not to be the case for STC (Flik et al.,
1990); the glyco group does not represent an antigenic 
site in this hormone.
If V contains the major antigenic site it needs to be 
discussed why the affinity for the antibody is 1 0 0  times 
lower than that of tSTC. It could be that V forms just a 
part of the antigenic site. It could also be due to the 
fact that V is monomeric and lacks three-dimensional 
folding. Obviously, more fragments need to be tested 
to be sure about the antigenic site in STC. The results 
show, however, that the currently available antibodies 
may recognize inactive STC forms. This conclusion is 
confirmed by the results obtained with tSTC'.
tSTC' showed similar antibody binding characteris­
tics as intact tSTC, but lost its bioactivity as mentioned 
before. Thus, non-bioactive STC lacking the first four 
amino acids would be measured in an ELISA as is 
native STC. Interestingly, immunization of rabbits with 
tSTC' resulted in a serum that only recognized frag­
ment V, exactly as the other antibodies raised against 
native STC (RADH-III, ECS-I, ECS-I1I; results not 
shown). It means that the antigenic site of tSTC' is 
unaltered whereas the receptor binding site is im­
paired.
Conclusion
We conclude that the bioactive site and the predom­
inant epitope of STC reside at different locations on 
the hormone. In tilapia and trout, the bioactive portion 
of STC appears to be the N-terminus, whereas the 
major antigenic site seems to be located in the midre­
gion. Physiological studies of STC hormone secretion 
and metabolic clearance require an antibody which 
recognizes only the biologically active hormone. There­
fore, it inevitable follows from the present study that 
new antibodies should be produced that only recognize 
the amino terminal part of the hormone. To reach this 
point the production of antibodies against hormone 
fragments (coupled to a carrier protein for immuniza­
tion) seems to be the most promising route.
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